Arthritis & Rheumatology News and Research

Latest Arthritis & Rheumatology News and Research

Merck agrees to pay $950 million in Vioxx safety probe

Merck & Co. will pay $950 million and one of its units will plead guilty to a criminal charge to resolve a U.S. probe of its illegal marketing of the painkiller Vioxx.

22 Nov 2011

Post-surgery death risk high among thinner people: Study

A new study has found that thinner people are at a higher risk of dying within 30 days of an operation than heavier people. The cause behind this trend is not clear.

22 Nov 2011

Cognitive-behavioral therapy safe and effective for juvenile fibromyalgia

A recent trial shows cognitive-behavioral therapy (CBT) reduces functional disability and depressive symptoms in adolescents with juvenile fibromyalgia. The psychological intervention was found to be safe and effective, and proved to be superior to disease management education.

22 Nov 2011

Titanium particles from artificial joints may play a direct role in painful inflammation

Many people with painful, creaky knees and hips find relief after replacing their bad joints with new artificial joints made from titanium. But some of these people develop painful inflammation that can lead to bone destruction and loosening of the new joint. A new study led by researchers at the University of Medicine and Dentistry of New Jersey and published by the Journal of Immunology suggests that tiny titanium particles that flake away from the artificial joints through normal wear and tear may play a direct role in that inflammation.

22 Nov 2011

New insights into immune-system changes that may trigger cartilage breakdown

Challenging long-held notions that osteoarthritis is a result mainly of wear and tear on the joints, researchers led by Dr. William H. Robinson of the Department of Veterans Affairs Palo Alto Health Care System and Stanford University have provided new insights into the immune-system changes that may trigger cartilage breakdown.

21 Nov 2011

EMA validates Pfizer's Market Authorisation Application for tofacitinib to treat rheumatoid arthritis

Pfizer Inc. announced today that its Market Authorisation Application for tofacitinib (development code CP-690,550), a novel, oral JAK inhibitor being studied for the treatment of moderate-to-severe active rheumatoid arthritis (RA), has been validated by the European Medicines Agency (EMA).

21 Nov 2011

Scientists show that the sense of smell can be improved

In a new study scientists at NYU Langone Medical Center have shown that the sense of smell can be improved. The new findings, published online November 20, 2011, in Nature Neuroscience, suggest possible ways to reverse the loss of smell due to aging or disease.

20 Nov 2011

Omega-3 linked with reduced joint pain and cognitive side effects of breast cancer therapy

"I know I need this medicine to help lower my chance of cancer recurrence, but it makes my joints ache and stiff. It makes me feel old and I am not sure I can take this medication much longer."

19 Nov 2011

Panel discussion on ethics behind sports concussion treatment

Experts from NYU Langone Medical Center and NYU School of Continuing and Professional Studies' Preston Robert Tisch Center for Hospitality, Tourism and Sports Management held a panel discussion Tuesday night on the ethics of who is responsible for ensuring appropriate medical treatment of an athlete that is injured - particularly if they may have a concussion.

19 Nov 2011

FDA approves EYLEA for treatment of wet Age-related Macular Degeneration

Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has approved EYLEA (aflibercept) Injection, known in the scientific literature as VEGF Trap-Eye, for the treatment of patients with neovascular (wet) Age-related Macular Degeneration (AMD) at a recommended dose of 2 milligrams every four weeks for the first 12 weeks, followed by 2 mg every eight weeks.

19 Nov 2011

FDA assigns new PDUFA date for Takeda's investigational type 2 diabetes therapy, alogliptin

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Global Research & Development Center, Inc., U.S., today announced that the company received notification from the U.S. Food and Drug Administration (FDA) that its review of investigational type 2 diabetes therapy alogliptin, and thus the fixed-dose combination therapy alogliptin/pioglitazone, will be delayed.

18 Nov 2011

Tonix to initiate TNX-102 PK and BA study for fibromyalgia

Tonix Pharmaceuticals Holding Corp., a specialty pharmaceutical company developing therapies for challenging disorders of the central nervous system, including fibromyalgia syndrome and post-traumatic stress disorder, will initiate a comparative pharmacokinetic and bioavailability study of TNX-102, a novel dosage oral formulation of cyclobenzaprine for the treatment of FM, following the U.S. Food and Drug Administration clearance of the Company's initial Investigational New Drug Application.

18 Nov 2011

The AJMS launches new series on 'Pathophysiology in Medicine'

As scientific research delves into the processes underlying human disease, doctors are challenged to integrate these new discoveries into patient care. To help bridge the gap between basic science research and clinical practice, a new series on "Pathophysiology in Medicine" begins this month in The American Journal of the Medical Sciences (The AJMS), official journal of the Southern Society for Clinical Investigation.

18 Nov 2011

NYU Langone cardiovascular experts present new research findings at AHA 2011

Experts from the Cardiac & Vascular Institute at NYU Langone Medical Center presented new research findings at the American Heart Association Scientific Sessions 2011 held November 12-16, 2011 in Orlando, Florida.

18 Nov 2011

Chloroquine-chemotherapy combination holds potential for metastatic breast cancer treatment

An anti-malaria drug used for more than 60 years is now being studied for use in breast cancer patients whose disease has not responded to traditional chemotherapy treatment.

18 Nov 2011

Researchers identify protein that affects production of extracellular vesicles

Researchers at NYU Langone Medical Center have discovered a protein called TAT-5 that affects the production of extracellular vesicles, small sacs of membrane released from the surface of cells, capable of sending signals to other cells.

17 Nov 2011

ACR special issue focuses on assessing adult pain

Assessment of patient outcomes allows physicians and researchers to measure the success or failure of diagnostics and treatments that patients receive. One set of measurement tools focuses on assessing adult pain and is included in a special issue of Arthritis Care & Research, a journal of the American College of Rheumatology (ACR), providing physicians and researchers with a single resource of 250 patient outcomes measurements in rheumatology.

17 Nov 2011

Psoriasis may alter cholesterol composition and decrease HDL function

Collaborative research from Perelman School of Medicine at the University of Pennsylvania has shown that psoriasis patients have an increased risk of heart attack, stroke and cardiovascular death, especially if the psoriasis is moderate to severe. Now, Penn researchers have discovered the potential underlying mechanism by which the inflammatory skin disease impacts cardiovascular health.

17 Nov 2011

NYU Langone recognized as leading cardiovascular hospital in the U.S.

NYU Langone Medical Center has been recognized as a leading cardiovascular hospital in the United States. The medical center received the Thomson Reuters Top 50 Cardiovascular Hospitals 2012 Award for its high-quality cardiovascular care and excellent performance in key clinical measures. The medical center is the only hospital in New York State to be honored with this year's award.

17 Nov 2011

TNF inhibitors may minimally increase risk of serious infections

Biologic drugs have revolutionized treatment of autoimmune diseases during the past decade despite belief there is an increased risk for serious infections from using them. But new research from the University of Alabama at Birmingham Center for Education and Research on Therapeutics reveals that a class of biologics called tumor necrosis factor antagonists, or TNF inhibitors, may only minimally increase risk compared to more traditional therapies.

17 Nov 2011